When to Undergo Genetic Testing for Breast Cancer: New Study Reveals Crucial Information
With approximately 55,000 cases of breast cancer reported among women in Italy every year, it is essential to prioritize prevention and early detection. In a recent study published in the Journal of Clinical Oncology, experts have shed light on when genetic testing for breast cancer should be carried out.
The study, in collaboration with the Association of American Breast Surgeons, emphasized the importance of identifying alterations in the BRCA1 and BRCA2 genes through genetic testing. According to geneticist and researcher Emanuela Lucci Cordisco from the Catholic University of Rome, the study suggests that genetic testing should be recommended for women diagnosed with breast cancer up to 65 years of age, rather than restricting it to those up to 40 years.
The significance of identifying gene alterations lies in the ability to understand the right therapy to follow. It is crucial for both prevention and treatment, as it can significantly impact the success of treatments and the overall outcome for patients.
However, the potential increase in the number of patients undergoing genetic testing poses a challenge for healthcare facilities in terms of the workload. It would require additional personnel and facilities to accommodate the surge in testing demands. Despite this, experts stress the importance of studying the DNA of each individual patient to identify potential genetic mutations that may increase the risk of developing breast cancer.
While environmental and lifestyle factors play a significant role in cancer development, genetic mutations indicate a higher probability of developing the disease. Therefore, urging individuals to undergo genetic testing can significantly contribute to early detection and personalized treatment plans.
As the fight against breast cancer continues, the emphasis on genetic testing as a crucial tool for prevention and treatment remains at the forefront. With the latest insights from the study, the medical community can work towards facilitating access to genetic testing and integrating it as a standard practice in breast cancer management.